Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancer by Salvatore, Ferla & Marcella, Bassetto
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
European Journal of Medicinal Chemistry
                                                
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa52205
_____________________________________________________________
 
Paper:
Bassetto, M., Ferla, S., Pertusati, F., Kandil, S., Westwell, A., Brancale, A. & McGuigan, C. (2016).  Design and
synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate
cancer. European Journal of Medicinal Chemistry, 118, 230-243.
http://dx.doi.org/10.1016/j.ejmech.2016.04.052
 
 
 
 
 
 
Released under the terms of a Creative Commons Attribution License (CC-BY).
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 Research paper
Design and synthesis of novel bicalutamide and enzalutamide
derivatives as antiproliferative agents for the treatment of prostate
cancer
Marcella Bassetto 1, Salvatore Ferla*, 1, Fabrizio Pertusati 1, Sahar Kandil,
Andrew D. Westwell, Andrea Brancale, Christopher McGuigan
School of Pharmacy and Pharmaceutical Sciences, Redwood Building, King Edward VII Avenue, CF10 3NB, Cardiff, Wales, UK
a r t i c l e i n f o
Article history:
Received 30 November 2015
Received in revised form
20 April 2016
Accepted 21 April 2016
Available online 22 April 2016
This work is dedicated to the memory of
Prof. Chris McGuigan, a great colleague and
scientist, invaluable source of inspiration
and love for research.
Keywords:
Bicalutamide
Enzalutamide
Prostate cancer
Perﬂuoroalkyl
Androgen receptor
Antiproliferative activity
a b s t r a c t
Prostate cancer (PC) is one of the major causes of male death worldwide and the development of new
and more potent anti-PC compounds is a constant requirement. Among the current treatments, (R)-
bicalutamide and enzalutamide are non-steroidal androgen receptor antagonist drugs approved also in
the case of castration-resistant forms. Both these drugs present a moderate antiproliferative activity and
their use is limited due to the development of resistant mutants of their biological target.
Insertion of ﬂuorinated and perﬂuorinated groups in biologically active compounds is a current trend
in medicinal chemistry, applied to improve their efﬁcacy and stability proﬁles. As a means to obtain such
effects, different modiﬁcations with perﬂuoro groups were rationally designed on the bicalutamide and
enzalutamide structures, leading to the synthesis of a series of new antiproliferative compounds. Several
new analogues displayed improved in vitro activity towards four different prostate cancer cell lines, while
maintaining full AR antagonism and therefore representing promising leads for further development.
Furthermore, a series of molecular modelling studies were performed on the AR antagonist confor-
mation, providing useful insights on potential protein-ligand interactions.
© 2016 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Prostate cancer (PC) is a leading cause of male death worldwide
and it is the most frequently diagnosed cancer among men aged
65e74 [1]. The prognosis varies greatly, being highly dependent on
a number of factors such as stage of diagnosis, race and age.
Currently, PC treatment includes androgen deprivation, surgery,
radiation, endocrine therapy and radical prostatectomy.
PC cell growth is strongly dependent on androgens, therefore
blocking their effect can be beneﬁcial to the patient's health. Such
outcomes can be achieved by antagonism of the androgen receptor
(AR) using anti-androgen drugs, which have been extensively
explored either alone or in combination with castration [2]. Fluta-
mide (Eulexin®) (1) (in its active form as hydroxyﬂutamide (2)),
bicalutamide (Casodex®) (3), nilutamide (Niladron®) (4) and
enzalutamide (previously called MDV3100) (Xtandi®) (5) are all
non-steroidal androgen receptor antagonists approved for the
treatment of PC (Fig. 1). In many cases, after extended treatment
over several years, these anti-androgens become ineffective and
the disease may progress to a more aggressive and lethal form,
known as castration resistant prostate cancer (CRPC). The major
cause of this progressive disease is the emergence of different
mutations on the AR, which cause the anti-androgen compounds to
function as agonists, making them tumour-stimulating agents [3].
Among the drugs used for the treatment of PC, bicalutamide and
enzalutamide selectively block the action of androgens while pre-
senting fewer side effects in comparison with other AR antagonists
[4e6]. The structure of these molecules is characterised by the
presence of a triﬂuoromethyl substituted anilide, which appears to
be critical for biological activity (Fig. 1). As a means to improve the
anti-proliferative activity of these compounds, and in order to
exploit the well established potential of the ﬂuorine atom in
enhancing the pharmacological properties and drug-like
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physicochemical characteristics of candidate compounds [7e9], a
wide array of diverse new structures has been rationally designed
and synthesised, through the introduction of ﬂuoro-, tri-
ﬂuoromethyl- and triﬂuoromethoxy groups in diverse positions of
both aromatic rings of the parent scaffolds. Our modiﬁcations
resulted in a marked improvement of in vitro anti-proliferative
activities on a range of human PC cell lines (VCap, LNCaP, DU-145
and 22RV1). In addition, we probed full versus partial AR antago-
nism for our new compounds.
2. Results and discussion
Triﬂuoromethyl and triﬂuoromethoxy functions were system-
atically inserted on both aromatic rings of bicalutamide and enza-
lutamide, with the aim to explore the effect of perﬂuoro groups on
their biological activity. As a means to further expand structure-
activity relationship studies, the insertion of different linkers was
also envisaged, along with the replacement of the bicalutamide
methyl group with a triﬂuoromethyl function.
The main proposed modiﬁcations are summarised in Fig. 2.
2.1. Chemistry
Several reported methods for the synthesis of racemic bicalu-
tamide were explored to ﬁnd a rapid methodology that would
allow the preparation of a wide range of new derivatives [10e12].
Modiﬁcation and optimization of these procedures led to the
development of the synthetic pathway shown in Scheme 1. Phe-
nylacrylamides 12e16 were prepared by reacting the correspond-
ing aniline (7e11) with methacryloyl chloride (6) in
dimethylacetamide (DMA), modifying a reported methodology
[10]. In particular, due to the presence of electron withdrawing
groups (nitro, cyano, triﬂuoromethyl) in different positions, ani-
lines 7e11 were in some cases (9 and 10 in particular) of low
reactivity towards nucleophilic displacement. Synthetic efforts
were made to achieve good yields (Supplementary data). Phenyl-
acrylamides 12e16 were converted into the corresponding epox-
ides 17e21 in the presence of a large excess of hydrogen peroxide
and triﬂuoroacetic anhydride in dichloromethane [11]. Opening of
the epoxide rings of 17e21 with commercially available phenols
and thiophenols gave a series of ethers (27e31) and thioether de-
rivatives (22e26), respectively, in good yields after puriﬁcation by
column chromatography [11]. Thioethers 22e25 were ﬁnally oxi-
dised to the corresponding sulfones 32e35 using mCPBA, main-
taining the temperature at 25 C [12]. Racemic bicalutamide (3) was
prepared as a positive control following this route.
Since R-bicalutamide is known to be themost active enantiomer
[13], chiral synthesis of selected R-bicalutamide analogues was
carried out as shown in Scheme 2. (R)-N-Methacryloylproline 37,
prepared using (R)-proline (36) and methacryloyl chloride (6), was
reacted with N-bromosuccinimide in DMF to afford bromolactone
38 as a single enantiomer [14]. Acid hydrolysis of 38 resulted in the
formation of bromohydrin acid 39, which was then converted into
the corresponding chiral anilide (40e41) [14]. Amide derivatives
40e41 were reacted with the sodium salt of different commercial
thiophenols in tetrahydrofuran to give, after puriﬁcation by silica
gel chromatography, the desired (R)-thioethers (42e44) [15]. Re-
action of amide 40with the sodium salt of 4-cyanophenol gave the
reference compound (S)-enobosarm (44e). Oxidation of thioethers
42e43 with mCPBA provided sulfones 45e46, with the desired R
absolute conﬁguration [12]. Reference (R)-bicalutamide (45a) was
prepared following this synthetic route.
For one of the most active compounds initially found, 23d,
replacement of the central methyl group with an extra tri-
ﬂuoromethyl function was planned and carried out (Scheme 3).
3-Bromo-1,1,1-triﬂuoroacetone (48) was coupled with thio-
phenol 47 to afford 49, which was then converted into cyano de-
rivative 50 using potassium cyanide and 25% sulfuric acid [16].
Intermediate 51 was obtained after reﬂuxing 50 in concentrated
HCl and glacial acetic acid. Coupling of 51 with commercially
available 4-nitro-3-(triﬂuoromethyl)aniline 8 yielded the desired
amide 52.
Several methods have been reported for the preparation of
enzalutamide, all showing as a synthetic challenge the formation of
the N-substituted thiohydantoin ring [17e19]. The method selected
in this study was a three-step synthesis involving the preparation
of different isothiocyanates (54e58), obtained in quantitative yield
after treating the corresponding aniline (7e10, 53) with thio-
phosgene (Scheme 4) [17]. Reaction conditions were optimised for
the different anilines used, with 9 and 10 requiring higher
Fig. 1. Structure of anti-androgen small molecules approved by FDA or in clinical development for the treatment of PC.
Fig. 2. Proposed modiﬁcations on bicalutamide and enzalutamide scaffolds.
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temperature, longer reaction time and the addition of extra
equivalents of thiophosgene due to their low reactivity. Strecker
reaction of substituted anilines (11, 53) with acetone and trime-
thylsilyl cyanide generated the desired cyanomines 59e60. Reac-
tion of 59e60 with isothiocyanates 54e58 in DMF followed by the
addition of HCl and MeOH gave the desired thiohydantoins 61e65.
The last reaction stepwas characterized by poor yields possibly due
to low reactivity and the formation of several side products (mainly
due to the degradation of the reagents into the original starting
anilines). Moreover, attempted preparation of enzalutamide de-
rivatives 71b and 71d, in which the nitro and cyano groups are
removed, was unsuccessful following this route.
An alternative method reported for the preparation of enzalu-
tamide was investigated to obtain 71b and 71d (Scheme 5) [19].
Scheme 1. Synthetic pathway for the synthesis of racemic bicalutamide analogues adapted from reported procedures [10e12]. Reagents and conditions: (a) 6 (8 equiv.), DMA, RT,
3 h; (b) H2O2 (4 equiv.)/(CF3CO)2O (5 equiv.), DCM, RT, 24 h; (c) NaH (1.2 equiv.), 17e21 (1.2 equiv.), THF, RT, 24 h; (d) mCPBA (1.4 equiv.), DCM, RT, 4e6 h.
Scheme 2. Synthesis of (R)-bicalutamide derivatives [12,14,15]. Reagents and conditions: (a) 6 (1 equiv.), 2N NaOH, acetone, 0 C to 10e11 C, 3 h; (b) NBS, DMF, argon, 3 days, RT
followed by H2O, RT, 12e24 h; (c) 24% HBr, reﬂux, 1 h; (d) 39 (1 equiv.), SOCl2 (1.2 equiv.), DMA, 10 C, 2 h followed by 7/9 (1 equiv.), DMA, RT, o.n.; (e) 40/41 (1 equiv.), phenol/
thiophenol (1.2 equiv.), 60% NaH (1.2 equiv.), THF, RT, 24 h; (f) mCPBA (1.4 equiv.), DCM, RT, 4e6 h.
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Commercially available 3-bromobenzotriﬂuoride (66) was coupled
with 2-aminoisobutyric-acid to obtain amino propionic acid
derivative 67, which was then converted into its methyl ester 68
after treatment with iodomethane. Reaction of 68 with different
isothiocynates (70b, d) yielded the desired thiohydantoins 71b and
71d. Following this procedure, standard enzalutamide (5) was also
prepared.
2.2. Antiproliferative assay
Antiproliferative activity of the newly synthesized compounds
was initially evaluated with an in vitro 2D monolayer assay using
four human prostate cancer cell lines (LNCaP, 22Rv1, VCaP, and
DU145). LNCaP, VCaP and 22Rv1 exhibit some androgen sensitivity,
whereas DU145 is hormone-insensitive. The assay allows deter-
mination of the compound's capacity to inhibit survival and/or cell
proliferation. The antiproliferative results are reported in Tables 1
and 2 (absolute IC50 in mM).
The overall activity of the four reference compounds (3, 5, 45a,
44e) is consistent with previous reported data for some of these
speciﬁc cell lines and it represents a conﬁrmation of the reliability
of the test [20e22]. 70% of our new derivatives performed better
than bicalutamide, either as a racemic mixture or pure R-isomer (3,
45a), signiﬁcantly improving its antiproliferative activity up to 50-
fold (overall antiproliferative activity in the four cell lines reported
as geometric mean).
Most inhibitors showed concentration-dependent activity
against the four prostate cancer cell lines, with mean IC50 values
ranging from 1.6 mM to >100 mM. Active inhibitors showed
sigmoidal concentrationeeffect curves with total cell kill at high
concentrations (Supplementary data). Although the overall anti-
proliferative activity seems to be the result of thewhole structure of
each single derivative, a general SAR can be identiﬁed, considering
three main structural components: linker X, aromatic ring A and
aromatic ring B. Thioether or ether compounds (X ¼ S or O) are
associated with better antiproliferative activity than the corre-
sponding sulfone derivatives (X ¼ SO2), with a decrease of effect in
the sulfones up to eight fold (i.e. 25l and 28l vs 35l; 23d & 28d vs
33d; 42d vs 45d; 22d & 27d vs 32d; 23c & 28c vs 33c). These data
are consistent with previous work, inwhich thioether derivatives of
SARMs (selective androgen receptor modulators) were found to be
more active than the corresponding sulfones [20]. However,
different newly prepared sulfones showed improved anti-
proliferative activity in comparison with the standard bicaluta-
mide, with a decrease of IC50 values up to two-fold (i.e. 33c, 33b,
45b, etc.). Replacement of the sulfur atomwith oxygen is in general
associated with retained activity (i.e. 23c vs 28c; 22c vs 27c), with
only few cases of decreased activity in comparison with the thio-
ether analogues (i.e. 25l vs 28l; 23d vs 28d), probably due to the
combined effect of the substituent on aromatic ring B and the
linker. Several new ether derivatives performed better than the
Scheme 3. Synthetic strategy used in the synthesis of 52. Reagents and conditions: (a) NaH (1 equiv.), THF, 0 C to RT, 3 h; (b) KCN (1.2 equiv.), 25% H2SO4, 0 C to RT, 20 h; c) HCl,
AcOH, reﬂux, 24 h; (d) 8, SOCl2 (1.3 equiv.), DMA, RT, 72 h.
Scheme 4. Synthetic strategy toward enzalutamide derivatives. Adapted from re-
ported procedure [17]. Reagents and conditions: (a) CSCl2 (1.5 equiv.), NaHCO3, H2O,
DCM, RT, 24 h; (b) TMSCN (5.1 equiv.), acetone, 80 C, 12 h; (c) DMF, RT 48 h, followed
by HCl, MeOH, reﬂux, 6 h.
Scheme 5. Synthetic strategy toward enzalutamide derivatives 71b-d. Adapted from a
reported procedure [19]. Reagents and conditions: (a) 2-aminoisobutyric acid
(1.5 equiv.), K2CO3 (6.5 equiv.), CuCl (0.2 equiv.), 2-acetylcyclohexanone (0.2 equiv.),
DMF, H2O, 105 C, 14 h; (b) MeI (1.2 equiv.), K2CO3 (1.2 equiv.), H2O, DMF, 40 C, 1 h; c)
CSCl2 (1.5 equiv.), NaHCO3, H2O, DCM, RT, 24 h; d) DMSO, IPAc, 84 C, 14 h.
M. Bassetto et al. / European Journal of Medicinal Chemistry 118 (2016) 230e243 233
Table 1
Antiproliferative activity for bicalutamide/enobosarm derivatives. All data are mean values from triplicate experiments.
Compound Ar (B ring) X R (A ring) Absolute IC50 (mM)
22Rv1 DU-145 LNCaP VCaP Geo.mean
3 (Bic.) 4-F-Ph SO2 4-CN, 3-CF3 49.58 49.20 45.27 68.37 52.42
44e (S-Eno) 4-CN-Ph O 4-CN, 3-CF3 24.77 44.55 20.90 24.47 27.41
45a (R-Bic.) 4-F-Ph SO2 4-CN, 3-CF3 46.25 45.41 45.20 51.61 47.05
22b 4-CF3-Ph S 4-CN, 3-CF3 NA
22c 3-CF3-Ph S 4-CN, 3-CF3 5.56 10.58 5.03 9.23 7.23
22d 2-CF3-Ph S 4-CN, 3-CF3 5.06 7.73 4.91 7.51 6.16
22h 4-OCF3-Ph S 4-CN, 3-CF3 46.62 64.01 42.81 40.33 47.64
22o 4-CF3-2-Pyridine S 4-CN, 3-CF3 53.91 84.10 80.72 89.27 75.60
23b 4-CF3-Ph S 4-NO2, 3-CF3 16.43 22.52 28.71 21.17 21.78
23c 3-CF3-Ph S 4-NO2, 3-CF3 5.07 8.73 6.44 8.64 7.04
23d 2-CF3-Ph S 4-NO2, 3-CF3 4.6 7.57 4.78 4.45 5.17
24a 4-F-Ph S 4-CN, 2-CF3 30.08 43.28 26.45 45.48 35.37
24b 4-CF3-Ph S 4-CN, 2-CF3 NA
24c 3-CF3-Ph S 4-CN, 2-CF3 15.16 21.05 11.26 23.48 17.04
24d 2-CF3-Ph S 4-CN, 2-CF3 11.64 18.42 10.72 18.27 14.32
25a 4-F-Ph S 4-NO2, 2-CF3 17.63 26.40 11.93 21.10 18.50
25b 4-CF3-Ph S 4-NO2, 2-CF3 14.63 19.20 8.66 17.07 14.28
25c 3-CF3-Ph S 4-NO2, 2-CF3 12.58 14.35 10.07 16.51 13.16
25d 2-CF3-Ph S 4-NO2, 2-CF3 11.97 17.53 11.66 12.79 13.30
25f 3,4-F-Ph S 4-NO2, 2-CF3 83.59 100 83.04 100 91.28
25g 2,4-F-Ph S 4-NO2, 2-CF3 14.93 21.43 11.00 16.64 15.56
25h 4-OCF3-Ph S 4-NO2, 2-CF3 61.92 69.59 100 100 81.02
25i 3-OCF3-Ph S 4-NO2, 2-CF3 15.80 21.63 9.15 15.88 14.93
25l 2-OCF3-Ph S 4-NO2, 2-CF3 4.64 6.57 3.31 5.27 4.80
25o 4-CF3-2-Pyridine S 4-NO2, 2-CF3 13.58 19.74 11.06 17.18 15.02
25p 5-CF3-2-Pyridine S 4-NO2, 2-CF3 11.52 14.03 5.52 17.36 11.15
26c 3-CF3-Ph S 4-CF3 18.57 30.71 22.56 19.50 22.44
26d 2-CF3-Ph S 4-CF3 5.20 8.76 7.22 5.86 6.63
26i 3-OCF3-Ph S 4-CF3 15.90 27.84 13.88 18.82 18.44
27b 4-CF3-Ph O 4-CN, 3-CF3 6.91 16.28 6.45 9.65 9.15
27c 3-CF3-Ph O 4-CN, 3-CF3 5.89 10.84 8.31 9.04 8.32
27d 2-CF3-Ph O 4-CN, 3-CF3 11.55 17.32 9.68 16.60 13.39
27f 3,4-F-Ph O 4-CN, 3-CF3 35.54 45.19 18.98 25.64 29.73
27g 2,4-F-Ph O 4-CN, 3-CF3 34.00 44.26 37.30 38.69 38.39
27h 4-OCF3-Ph O 4-CN, 3-CF3 17.20 18.36 13.56 17.59 16.57
27i 3-OCF3-Ph O 4-CN, 3-CF3 9.79 16.36 9.83 9.91 11.17
27o 4-CF3-2-Pyridine O 4-CN, 3-CF3 100 100 100 100 100
28b 4-CF3-Ph O 4-NO2, 3-CF3 16.19 25.93 17.24 10.91 16.76
28c 3-CF3-Ph O 4-NO2, 3-CF3 8.58 10.02 9.91 10.28 9.68
28d 2-CF3-Ph O 4-NO2, 3-CF3 20.16 35.20 22.60 27.16 25.69
28e 4-CN-Ph O 4-NO2, 3-CF3 30.92 32.68 18.69 26.88 26.69
28f 3,4-F-Ph O 4-NO2, 3-CF3 18.54 21.61 14.50 18.92 18.21
28g 2,4-F-Ph O 4-NO2, 3-CF3 20.16 22.39 10.06 20.92 17.56
28h 4-OCF3-Ph O 4-NO2, 3-CF3 7.53 10.43 17.66 19.55 12.83
28i 3-OCF3-Ph O 4-NO2, 3-CF3 9.31 13.14 9.95 9.60 10.40
28l 2-OCF3-Ph O 4-NO2, 3-CF3 6.60 9.88 7.04 9.61 8.15
28m 4-CN,2-CF3-Ph O 4-NO2, 3-CF3 5.55 7.65 5.69 8.38 6.71
28n 4-CN,3-F-Ph O 4-NO2, 3-CF3 11.77 16.39 7.71 12.39 11.65
28o 4-CF3-2-Pyridine O 4-NO2, 3-CF3 35.22 100 36.51 100 59.88
29b 4-CF3-Ph O 4-CN, 2-CF3 29.91 32.39 28.61 23.02 28.26
29c 3-CF3-Ph O 4-CN, 2-CF3 18.70 32.12 15.23 21.59 21.08
29d 2-CF3-Ph O 4-CN, 2-CF3 19.60 33.17 14.03 21.93 21.15
29e 4-CN-Ph O 4-CN, 2-CF3 42.935 100 34.722 61.370 55.00
29f 3,4-F-Ph O 4-CN, 2-CF3 37.03 41.93 34.80 47.18 39.95
29g 2,4-F-Ph O 4-CN, 2-CF3 60.92 99.48 30.64 50.62 55.37
29h 4-OCF3-Ph O 4-CN, 2-CF3 27.99 34.64 27.65 22.37 27.83
29i 3-OCF3-Ph O 4-CN, 2-CF3 28.65 35.86 63.39 56.34 43.76
29l 2-OCF3-Ph O 4-CN, 2-CF3 16.68 27.09 33.83 43.85 28.61
29m 4-CN,2-CF3-Ph O 4-CN, 2-CF3 18.45 27.52 9.39 17.70 17.04
29n 4-CN,3-F-Ph O 4-CN, 2-CF3 45.34 68.78 78.27 77.20 65.89
29o 4-CF3-2-Pyridine O 4-CN, 2-CF3 100 100 100 100 100
30b 4-CF3-Ph O 4-NO2, 2-CF3 18.93 22.08 13.57 18.56 18.01
30c 3-CF3-Ph O 4-NO2, 2-CF3 15.17 18.14 12.93 19.34 16.20
31c 3-CF3-Ph O 4-CF3 25.68 27.45 18.16 18.64 22.100
31d 2-CF3-Ph O 4-CF3 6.42 26.41 6.98 11.49 10.80
31i 3-OCF3-Ph O 4-CF3 15.43 29.40 2.16 4.28 8.05
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standard (S)-enobosarm (44e), improving its activity up to 4-fold
(i.e. 28m, 28l, 27c, etc.). Modiﬁcations on aromatic ring A do not
appear to signiﬁcantly affect antiproliferative activity.
Structural modiﬁcations on the B ring profoundly inﬂuence the
antiproliferative effect, improving or totally abolishing activity. In
particular, replacement of the original ﬂuorine in the para position
with a more lipophilic and bulkier triﬂuoromethyl moiety is asso-
ciated with an improvement of anti-proliferative activity of an
average of two fold (i.e. 3 vs 32b; 45a vs 45b; 25a vs 25b; 34a vs
34b; 35a vs 35b). Introduction of the triﬂuoromethoxy group in the
Table 1 (continued )
Compound Ar (B ring) X R (A ring) Absolute IC50 (mM)
22Rv1 DU-145 LNCaP VCaP Geo.mean
32b 4-CF3-Ph SO2 4-CN, 3-CF3 21.54 32.84 20.05 29.11 25.345
32c 3-CF3-Ph SO2 4-CN, 3-CF3 20.954 39.112 14.94 39.66 26.40
32d 2-CF3-Ph SO2 4-CN, 3-CF3 46.55 55.03 42.74 58.55 50.32
32h 4-OCF3-Ph SO2 4-CN, 3-CF3 17.02 27.28 31.64 32.81 26.35
32o 4-CF3-2-Pyridine SO2 4-CN, 3-CF3 100 100 100 100 100
33b 4-CF3-Ph SO2 4-NO2, 3-CF3 18.66 24.68 17.94 31.53 22.59
33c 3-CF3-Ph SO2 4-NO2, 3-CF3 16.14 31.62 16.20 30.83 22.47
33d 2-CF3-Ph SO2 4-NO2, 3-CF3 18.56 37.51 25.70 27.55 26.50
34a 4-F-Ph SO2 4-CN, 2-CF3 77.00 100 91.59 65.22 82.36
34b 4-CF3-Ph SO2 4-CN, 2-CF3 27.87 44.56 32.93 43.29 36.48
34c 3-CF3-Ph SO2 4-CN, 2-CF3 34.35 45.94 32.08 44.92 38.83
34d 2-CF3-Ph SO2 4-CN, 2-CF3 98.82 100 74.02 100 92.48
35a 4-F-Ph SO2 4-NO2, 2-CF3 46.67 60.73 38.65 58.21 50.25
35b 4-CF3-Ph SO2 4-NO2, 2-CF3 25.39 40.91 29.30 46.89 34.56
35c 3-CF3-Ph SO2 4-NO2, 2-CF3 18.14 32.01 16.77 38.66 24.77
35d 2-CF3-Ph SO2 4-NO2, 2-CF3 28.33 46.09 20.46 38.58 31.86
35f 3,4-F-Ph SO2 4-NO2, 2-CF3 33.58 48.09 19.47 37.26 32.90
35g 2,4-F-Ph SO2 4-NO2, 2-CF3 30.24 46.58 17.92 57.96 34.78
35h 4-OCF3-Ph SO2 4-NO2, 2-CF3 100 100 100 100 100
35i 3-OCF3-Ph SO2 4-NO2, 2-CF3 17.96 27.72 12.23 20.27 18.74
35l 2-OCF3-Ph SO2 4-NO2, 2-CF3 28.79 38.97 17.77 51.74 31.87
35o 4-CF3-2-Pyridine SO2 4-NO2, 2-CF3 100 100 100 100 100
35p 5-CF3-2-Pyridine SO2 4-NO2, 2-CF3 46.46 57.66 45.03 58.47 51.54
42b (R) 4-CF3-Ph S 4-CN, 3-CF3 9.75 17.18 14.45 9.28 12.24
42c (R) 3-CF3-Ph S 4-CN, 3-CF3 13.14 19.45 14.31 8.91 13.43
42d (R) 2-CF3-Ph S 4-CN, 3-CF3 5.30 7.69 7.90 2.95 5.55
42g (R) 2,4-F-Ph S 4-CN, 3-CF3 17.15 28.46 25.19 18.29 21.78
42h (R) 4-OCF3-Ph S 4-CN, 3-CF3 28.81 29.78 19.83 17.39 23.32
43a (R) 4-F-Ph S 4-CN, 2-CF3 NA
45b (R) 4-CF3-Ph SO2 4-CN, 3-CF3 20.19 26.76 17.47 31.42 23.34
45c (R) 3-CF3-Ph SO2 4-CN, 3-CF3 25.66 45.19 13.17 39.92 27.95
45d (R) 2-CF3-Ph SO2 4-CN, 3-CF3 34.75 44.31 32.23 37.30 36.89
45g (R) 2,4-F-Ph SO2 4-CN, 3-CF3 42.25 60.20 42.26 60.90 50.58
45h (R) 4-OCF3-Ph SO2 4-CN, 3-CF3 18.82 31.56 18.91 31.195 24.33
46a (R) 4-F-Ph SO2 4-CN, 2-CF3 100 100 85.55 100 96.17
52 2-CF3-Ph S 4-NO2, 3-CF3 1.28 2.40 0.72 2.78 1.57
Table 2
Antiproliferative activity for enzalutamide derivatives. All data are mean values from triplicate experiments.
Compound R1 R2 IC50 (mM)
22Rv1 DU-145 LNCaP VCaP Geo.mean
61b 4-CN, 3-CF3 4-CF3 63.58 100 9.37 30.06 36.58
62b 4-NO2, 3-CF3 4-CF3 100 100 2.12 73.13 35.28
62c 4-NO2, 3-CF3 3-CF3 100 100 15.16 100 62.40
63b 4-CN, 2-CF3 4-CF3 100 100 8.36 100 53.78
63c 4-CN, 2-CF3 3-CF3 59.31 100 18.3 100 57.40
64b 4-NO2, 2-CF3 4-CF3 16.39 100 3.73 100 27.96
64c 4-NO2, 2-CF3 3-CF3 5.01 7.88 4.07 13.26 6.80
65b 3-CF3 4-CF3 100 100 5.95 72.40 45.56
65c 3-CF3 3-CF3 60.68 100 5.61 75.66 40.05
71b 4-CF3 3-CF3 92.47 100 16.59 100 57.34
71d 2-CF3 3-CF3 100 100 28.28 100 77.79
5 (Enzal.) e e 31.76 32.27 11.47 53.04 28.10
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para position does not have a signiﬁcant effect or slightly decreases
the activity if compared with eCF3 analogues. The 4-CN group
present in (S)-enobosarm (44e) slightly improves or leaves unal-
tered the antiproliferative activity, depending on the X linker and
the substituent in the A ring (44e, 28e, 29e). Repositioning of the
triﬂuoromethyl group from the para to the meta and the ortho
position greatly improves antiproliferative activity up to ten-fold.
The best results were obtained with a substituent in position
ortho, either a CF3 (23d) or an OCF3 (25l) group. The IC50 values for
each new derivative appear to be a combination of the substituent
in the meta or ortho position of aromatic ring B, the linker (thio-
ether analogues are the most active) and the substituent in the A
ring (nitro derivatives perform slightly better than cyano ana-
logues). Generally, all meta and ortho substitutions on the B ring
performed better than standard bicalutamide, leading to a signiﬁ-
cant activity improvement. Replacement of the phenyl ring B with
either a 4-triﬂuoromethyl pyridine or a 5-triﬂuoromethyl pyridine
abolishes activity with only few exceptions (25o, 25p), which are
probably a consequence of the presence of a 4-NO2-2-CF3 aromatic
substituent in the A ring. Introduction of a second ﬂuoro substit-
uent in the B ring, such as a 2,4-ﬂuoro, 2,3-ﬂuoro, 4-CN,3-F or 4-
CN,2-CF3, is in general associated with a better activity proﬁle if
compared with standard bicalutamide and enobosarm. In partic-
ular, the introduction of an extra triﬂuoromethyl group in the ortho
position of enobosarm aromatic ring B improved its anti-
proliferative activity up to 4-fold (28m and 29m vs 44e).
No substantial differences were found between racemic and
chiral (R)-bicalutamide derivatives (22d vs 42d; 22c vs 42c), con-
ﬁrming that the observed superior efﬁcacy of the R-bicalutamide is
mainly due to metabolic properties [13].
Interestingly, the best-performing new compound was 52, in
which the central methyl group is replaced with a triﬂuoromethyl
function. The IC50 (geometric mean of the overall antiproliferative
activity in the four cell lines) is 3.5-fold better than its methyl
analogue (23d), and the improvement is evident if compared with
bicalutamide (50-fold).
Considering antiproliferative activity for each individual cell
line, most of our compounds showed interesting results in all four
cell types, with the best results found for those cells expressing the
androgen receptor, such as LNCaP (themost sensitive cell line to the
new derivatives). This evidence suggests that the newly syn-
thesised structures retain an antagonistic effect on the androgen
receptor. Signiﬁcant antiproliferative activity was also found in the
DU-145 cell line (the least sensitive to our new molecules), which
does not express the androgen receptor and is insensitive to
androgen activity, suggesting that also a different antiproliferative
mechanism could be involved, along with the canonical anti-
androgen receptor action. This potential off-target effect seems to
be present also in the parent bicalutamide (3, 45a), which shows
similar IC50 values across the four cell lines, and might have been
enhanced by the newly introduced modiﬁcations.
Newly synthesized enzalutamide analogues showed reduced
activity in the antiproliferative assay in comparison with standard
enzalutamide, with the only exception being 64c. However, the
new modiﬁcations clearly inﬂuenced the activity on LNCaP cells,
improving enzalutamide IC50 up to ﬁve-fold (62b). The total
absence of activity in the DU-145 cell line could be an indication of
a pure anti-androgenic effect for these new compounds. Replace-
ment of the original enzalutamide substituents in aromatic ring A
with a para triﬂuoromethyl group is the most effective modiﬁca-
tion, while modiﬁcations on the B ring do not appear to signiﬁ-
cantly affect activity.
As a general consideration on the antiproliferative results, the
introduction/change of position of triﬂuoromethyl and tri-
ﬂuoromethoxy groups emerges as an interesting strategy to
improve the biological effects of the parent molecules.
2.3. Androgen receptor (AR) agonist/antagonist assay
Twenty-two derivatives were selected for the evaluation of their
AR antagonist/agonist effect using the GeneBLAzer® Betalactamase
reporter technology for Nuclear receptors (NRs), to assess whether
the antiproliferative activity found is related to any interference
with the AR function [23].
All tested compounds were found to be antagonist of the
androgen receptor in a single concentration antagonism experi-
ment (10 mM concentration, antagonistic effect > 80%), which
measures their ability to reduce the receptor activation induced by
the known androgen receptor agonist R1881 [24,25]. A 10-
concentration antagonism assay (Supplementary data) showed
that the new molecules possess an antagonistic IC50 in the same
range of reference (R)-bicalutamide and enzalutamide (Table 3).
The (R)-bicalutamide IC50 is comparable with previously reported
values in similar assays [26,27].
In the bicalutamide-derived series of analogues, the antago-
nistic effect is not inﬂuenced by the substituents in aromatic ring A
(28d vs 23d vs 25d vs 22d), with a small beneﬁcial effect found for
both the O and S linkers (28d vs 23d vs 33d) in the racemic de-
rivatives, whereas the SO2 linker is the most effective found for the
(R) structures (42b vs 45b and 45h). Structural modiﬁcations on
aromatic ring B have a major inﬂuence for antagonistic activity;
substitutions in the meta position are associated with improved
IC50 values (i.e. 28d, 28l, 23d), substitutions in the ortho position are
well tolerated (i.e. 23c), while substitutions in the para position
result in higher IC50 values (i.e. 42b) if compared with (R)-bicalu-
tamide. Overall, the results obtained fall in a similar range, with no
signiﬁcant changes in the anti-androgenic activity in comparison
with control bicalutamide. The presence of a cyano group in the
para position of ring B (28m, 28n), as in control (S)-enobosarm, is
associated with the best antagonistic activity, while the
Table 3
AR antagonist/agonist assay results. * Compounds were considered full antagonist if
at a single concentration of 10 mM the reduction of receptor activation by R1881 was
greater than 80%; ** Compound at 10 mM concentration in absence of R1881 was
used; *** Compounds tested at 10 different concentrations; **** Due to poor solu-
bility, the highest concentration used was 1 mM; N.E, no antagonistic effect.
Compound Antagonistic effect (%)* Agonistic effect (%)** IC50 (mM)***
45a (R-Bic.) 83 5 0.490
44e (S-Enob.) 59 26 0.0364
5 (Enzal.) 95 N.E. 0.361
22d 93 11 0.425
23c 93 N.E. 0.625
23d 91 4 0.280
25d 94 2 0.332
28d 94 7 0.183
28h 96 e 0.625
28i 106 e 0.407
28l 103 N.E. 0.198
28m 108 N.E. 0.0722
28n 65**** N.E. 0.0492
29m 99 e 0.736
33d 85 1 0.811
33c 104 e 1.07
42b 92 9 2.170
45b 93 e 0.775
45h 61**** N.E. 0.777
52 110 e 0.245
62b 91 e 0.0803
63b 96 e 0.402
64b 102 e 0.265
64c 87 e 0.111
65c 100 e 0.123
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introduction of a second substituent is tolerated. Compound 52, the
best performing in the antiproliferative assay, showed an antago-
nistic IC50 comparable to the one of (R)-bicalutamide. Considering
the enzalutamide series, no signiﬁcant change in the antagonistic
effect was observed for the new derivatives tested.
For 14 compounds, a further analysis was performed in order to
verify any potential agonistic effect on the androgen receptor. The
compoundswere tested at a single concentration (10 mM) under the
same experimental conditions used for the antagonistic assay, in
the absence of R1881. All new derivatives showed either total
absence or an agonistic effect <10% (not signiﬁcant), conﬁrming
their full antagonistic behaviour. The partial agonist nature of (S)-
enobosarm (44e) was also conﬁrmed in our assay: after an initial
antagonistic activity at low concentration (best antagonistic IC50), it
acts as an agonist, activating the androgen receptor (agonistic effect
>20%). Interestingly, the new ether analogues, which could be
considered as enobosarm derivatives, were found to be full AR
antagonists (i.e. 28m, 28n, 25d, 28l).
The AR antagonist/agonist assay conﬁrmed a pure AR antago-
nistic nature for the newly prepared compounds, which showed a
concentration-dependent antagonistic activity. Moreover, an ac-
tivity switch from partial agonist to full antagonist can be observed
for our enobosarm analogues.
No correlation between AR assay and antiproliferative data can
be identiﬁed, implying that other modes of action or other pa-
rameters could play an important role in the antiproliferative ac-
tivity found for our new compounds.
2.4. Molecular modelling studies
Due to the retained activity of the newly synthesised com-
pounds on the AR, and in an attempt to investigate the switch from
partial agonist to full antagonist found for the newly prepared
enobosarm derivatives, a series of molecular modelling analyses
was designed and carried out.
2.4.1. AR antagonist conformation homology model
The functional switch from the open (antagonist) to the closed
(agonist) conformation of the AR is caused by the movement of
helix 12 (AR-H12), one of the 12 helices that deﬁne the ligand-
binding domain (LBD) [28,29]. The crystal structure of the com-
plex bicalutamide-AR is only available in the closed conformation
due to the W741L mutation (PDB ID: 1Z95), which causes bicalu-
tamide to occupy the AR binding site in an agonist fashion, allowing
the closure movement of helix 12 and therefore the activation of
the AR [28,29]. For the purpose of this part of the study, a homology
model of the human WT-AR open conformation was built, using a
single template approach in the MOE2014 homology modelling
tool following a previously reported methodology [30]. The crystal
structure of the progesterone receptor in its open antagonistic form
(PDB ID: 2OVM) was used as template, considering the good
sequence identity (54%) with the human AR [31]. The ﬁnal 3D
model was obtained as the Cartesian average of 10 generated in-
termediate models [32]. Validation of the new model was per-
formed using the Rampage Server, the Errat plot and calculating the
RMSD with the 2AM9 crystal structure [33e35]. Fig. 3 shows the
shift of helix 12 between the new model and the mutated AR-
bicalutamide crystal (PDB ID: 1Z95) [28].
2.4.2. Docking studies
Docking of (R)-bicalutamide was performed in the LBD of the
new model to evaluate its predicted antagonistic binding mode. As
shown in Fig. 4, docked bicalutamide occupies the binding site in
proximity of Trp741, forming a H-bond with Asn705 through its
hydroxyl group, and most importantly interacting with Arg752
through a second H-bond with its cyanide nitrogen [36]. A direct
comparison with the bicalutamide-resistant AR crystal (Fig. 5)
suggests that the sulfone ring orientation of the docking pose is the
most plausible considering the presence of Trp741 and the position
of helix 12. In fact, in the crystal, due to a W741L mutation, the
sulfone aromatic ring is pointing down towards the centre of the
protein, lying in the position that would be occupied by the Trp741
indole ring, allowing helix 12 closure [36]. The presence of Trp741
in the model does not allow this disposition (steric clash), orienting
aromatic ring B toward helix 12, thus blocking its closure. Docking
Fig. 3. Superposition between the crystal structure of the AR in the closed form (PDB
ID: 1Z95) (pink) and the new open AR model (light blue). Mutated Leu741 (pink) re-
duces the steric hindrance in comparison with the non-mutated Trp741 (light blue).
Co-crystallised bicalutamide (carbon atoms in salmon) is shown as stick model. (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to
the web version of this article.)
Fig. 4. Docking of (R)-bicalutamide (carbon atoms in pink) in the AR homology model
(light blue). Bicalutamide occupies the binding site in proximity of Trp741. The occu-
pational molecular surface around the active site is shown in grey. (For interpretation
of the references to colour in this ﬁgure legend, the reader is referred to the web
version of this article.)
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of the more rigid enzalutamide (Fig. 6) conﬁrms the proposed
antagonistic binding mode (comparable to the crystal structure of
AR-LDB in complex with an enzalutamide-like compound, PDB ID:
3V49) [37].
Fig. 7 shows the docking of two newly designed compounds
(28m, 33d, 52) in the AR homology model. The three compounds
show a consistent binding mode, occupying the LBD in the same
manner as bicalutamide, maintaining the same key interactions,
consistently with the AR assay results.
Replacement of the ﬂuorine substituent in the B ring with a
bigger group such as triﬂuoromethyl or triﬂuoromethoxy,
increasing the steric hindrance of this part of the molecule, could
allow the overcoming of bicalutamide resistance mechanism. This
speculation is supported by the docking of 33d in the mutant AR
crystal structure 1Z95: as shown in Fig. 8, the bulkier substituent in
the B ring does not ﬁt in the AR closed conformation, even in the
presence of the adaptive mutationW741L, as indicated by the close
proximity of ring B to the protein surface. Biological conﬁrmation of
this effect will be the focus of future studies.
Molecular docking of the new enobosarm derivatives (i.e. 28d,
28m, 28n, 28l, 25d) was performed on the crystal structure of
closed-conformation WT-AR in complex with (S)-enobosarm (PDB
ID: 3RLJ) [38], in order to explain the observed activity switch from
partial AR agonist to full antagonist. (S)-Enobosarm, after binding
the AR and acting as antagonist, activates the receptor by favouring
the closure movement of helix 12 even in the absence of theW741L
mutation. This movement, as shown in the crystal structure, is
made possible by the more ﬂexible and less bulky oxygen linker,
which allows a binding conformation similar to the one found for
bicalutamide in the W741L AR mutant crystal structure (Fig. 9).
Docking results show that the replacement of the cyano substituent
in aromatic ring B with a larger group (i.e. 2-OCF3 in 28l or 2-CF3 in
28d), or the introduction of a second aromatic substituent (i.e. 2-
CF3 in 28m), might lead to structural clashes with helix-12, con-
ﬁrming that these new enobosarm derivatives could impede the
movement of helix 12 to the AR-closed conformation, hence the
absence of any residual AR agonistic activity (Fig. 10).
The results obtained for our new enobosarm analogues might
represent a further indication that the newly inserted structural
modiﬁcations could play a role in overcoming the problem of
bicalutamide-induced AR mutation W741L.
2.4.3. Molecular dynamics simulations
To further conﬁrm the reliability of the new homology model,
and consequently support the speculations on the binding mode
proposed for the newly synthesized compounds, 5 ns molecular
dynamics (MD) simulations for selected derivatives (45a, 23d, 25d,
28d, 33d, 62b), either free in solution or in complex with the AR,
were performed. These structures were selected in order to cover
the range of activities found in the AR antagonist assay. The MD
output results were used to compute DGbinding energy calculations
of the ligand-protein complexes (Table 4).
The stability showed by most of the ligand-protein systems
during the simulations could be a consequence of the active site
composition, mainly formed by hydrophobic amino acids (Met745,
Met787, Leu707, Leu704, Leu712, Val746, Trp741, Phe764, etc.),
which provides an ideal environment for the lipophilic nature of
these ﬂuorinated molecules. Moreover, the formation of two
hydrogen bonds in the bicalutamide/enobosarm derivatives, both
present during the entire MD duration, with Arg752 and Asn705,
further contribute to the system stability, allowing the molecules to
maintain a stable conformation in the active site. The lowest
calculated DGbinding was obtained for 62b, whereas 33d, a deriva-
tive with one of the highest antagonistic IC50 values, showed the
highest energy result. Interestingly, a similar correlation between
the calculated DGbinding energy and the AR antagonistic IC50 was
found for all the compounds studied. Enzalutamide derivative 62b
showed the best result in terms of DGbinding, conﬁrming the best
antagonistic IC50 value obtained from the assay and highlighting
the high afﬁnity of the rigid enzalutamide-like structure for the
androgen receptor. The DGbinding/AR antagonistic IC50 correlation
might represent a further conﬁrmation of the reliability of the new
AR homologymodel and of the proposed bindingmode for the new
ﬂuorinated compounds.
2.5. In vitro metabolic stability, cell permeability and cytotoxicity
studies
The signiﬁcant improvement obtained with the newly synthe-
sized analogues in the antiproliferative assay, which is associated
with retained AR antagonistic activity in comparison with the
reference compounds, could be a consequence of an off-target ef-
fect, already present in the parent structures and enhanced by the
new modiﬁcations, or a consequence of altered cellular meta-
bolism, stability and/or cell permeability of the newmolecules, due
to their high ﬂuorine content.
In order to address these two points, additional in vitro studies
on a selection of our most active compounds (22c, 22d, 23c, 23d,
27b, 28m, 33d, 42b, 42c) were performed. Metabolic stability, cell
permeability and general cytotoxicity were evaluated. (R)-Bicalu-
tamide (45a) and (S)-enobosarm (44e) were used in control
experiments.
Fig. 5. Comparison between our AR model (light blue) and bicalutamide-resistant AR
crystal 1Z95 (pink). Crystallised (carbon atoms in salmon) and docked bicalutamide
(carbon atoms in pink) highlighted. (For interpretation of the references to colour in
this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 6. Docking of enzalutamide (carbon atoms in salmon) in the AR homology model
(light blue). The occupational molecular surface around the active site is shown in grey.
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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2.5.1. Metabolic stability in liver microsomes
The selected compounds together with the controls were tested
for their stability (oxidative metabolism being the predominant
type of biotransformation) in human liver microsomes (phase I
drug metabolism). The tested compounds were incubated for
45 min with pooled liver microsomes (Supplementary data), and
the intrinsic clearance (CLint) and half-life (t1/2) values were
calculated based on 5 time points (Table 5). Bicalutamide, as re-
ported in the literature, mainly undergoes oxidation in humans by
Fig. 7. Predicted binding mode of new derivatives 28m, 33d and 52 in the AR homology model.
Fig. 8. Docking of 33d (carbon atoms in light pink) in the 1Z95 crystal structure. The
red circle highlights how the ring B of the new compound is in close proximity to the
protein surface, potentially causing steric clashes that might impede the helix 12
movement to the closed conformation of the W741L AR mutant. The occupational
molecular surface of the binding site is shown in grey. (For interpretation of the ref-
erences to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
Fig. 9. Superimposition between the crystal structure of WT-AR co-crystallised with
(S)-enobosarm (green) and the W741L-AR co-crystallized with bicalutamide (salmon).
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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cytochrome P450 enzymes [26].
As expected, intrinsic clearance (Clint) is high and, as conse-
quence, t1/2 is very low for 22c, 22d, 23c, 23d, 42b, 42c. These
compounds are thioethers and therefore they might undergo rapid
oxidation of their sulﬁde linker to the corresponding sulfoxide and
eventually to the sulfone. Ether derivatives 28m, 27b and (S)-
enobosarm and sulfones 33d and (R)-bicalutamide show lower Clint
and higher t1/2, with some of them showing complete metabolic
stability (no loss of the parent detected during the assay). Oxidative
metabolism seems to affect mainly the thioether linker with a small
effect on the aromatic systems.
Interestingly, introduction of a triﬂuoromethyl group in the ar-
omatic ring (33d) completely abolishes any oxidative metabolism
on the ring itself, doubling the t1/2 in comparison with (R)-bicalu-
tamide. The signiﬁcant antiproliferative activity found for thioether
and ether derivatives does not seem to be caused by any oxidative
metabolite, as indicated by the high stability of ether analogues and
by the decrease in antiproliferative activity found for the respective
sulfone derivatives. Moreover, these results suggest that ether de-
rivatives have the best antiproliferative and stability (low intrinsic
clearance) proﬁle, making them good potential drug candidates.
2.5.2. Caco-2 cell permeability
An in vitro Caco-2 bi-directional permeability assay was per-
formed to gain information on membrane penetration, efﬂux from
cells and possible interaction with the P-glycoprotein (P-gp) for the
new compounds. The data obtained are reported in Table 6 as
apparent permeability (Papp) and efﬂux ratio. Generally, com-
pounds with a Papp A / B between 2 and 20  106 cm s1 are
considered as medium permeability drugs, whereas an efﬂux ratio
(BA/AB) higher than 2 is an indication that the compound could be
a substrate for a drug transporter (i.e. P-gp, BCRP) and undergo
active efﬂux to the extracellular compartment. These transporters
are all over-expressed in cancer cells and are commonly respon-
sible for drug resistance [21,39].
(R)-Bicalutamide (45a) shows a Papp A / B value of
32.0  106 cm s1, which is comparable to the one reported in
literature (22.1  106 cm s1), as both of these values would fall
into the rank order category of good permeability [21]. Under the
test conditions the Papp B / A value was found to be
38.1  106 cm s1, indicating membrane permeability in both
directions for (R)-bicalutamide. The calculated efﬂux ratio (BA/AB)
of 1.19 indicates that (R)-bicalutamide is not an efﬁcient substrate
for transporters, in discordance with published data, in which
bicalutamide shows an efﬂux ratio (BA/AB) of 5.4 [21]. This
discrepancy could be a consequence of using (R)-bicalutamide
(45a), since bicalutamide enantiomers have different metabolism,
permeability and absorption properties in vivo, which inﬂuence
their biological activity [13] and possibly the interactionwith the P-
glycoprotein. Moreover, several experimental variables can inﬂu-
ence the transport of compounds in both membrane directions.
Due to this variability, the Caco-2 cell data have been used only to
verify if any relevant difference in cell permeability is present
among the tested compounds. The reliability of our assay and the
functional presence of the protein transporters were evaluated
using two standard reference compounds (atenolol for low
permeability and propranolol for high permeability) and one
known P-glycoprotein substrate (talinolol) (Supplementary data).
The new molecules appear to be moderately permeable (2<Papp
A/ B>20  106 cm s1), with a low tendency to efﬂux from the
cell. Differences between racemic and (R) derivatives are evident
comparing compounds 22c and 42c, in which the pure (R) enan-
tiomer has an increased efﬂux ratio, still lower than 2. Overall, the
Fig. 10. A) (S)-Enobosarm co-crystallized in the WT-AR closed conformation (PDB ID: 3RLJ). B) Docking of 28d (carbon atoms in turquoise) and 28l (carbon atoms in white) in the
3RLJ crystal structure. Replacement of the cyano substituent with a bulkier group might cause structural clashes (red circles) with helix-12. (For interpretation of the references to
colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Table 4
Calculated ligand-interaction energies for the compounds analysed by Molecular
Dynamics and antagonistic IC50 values.
Compound DGbinding (kJ/mol) IC50 (mM)
62b 13.425 0.0803
28d 9.586 0.183
23d 8.909 0.280
25d 6.793 0.332
45a (R-bic.) 2.521 0.490
33d 0.781 0.811
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results obtained suggest that these compounds do not show any
signiﬁcant difference in cell permeability in comparison with the
standards, therefore no correlation can be identiﬁed between
antiproliferative data and cell permeability properties.
2.5.3. Cell viability assay (MTT)
A MTT cell viability assay was performed in a human hep-
atocarcinoma (HepG2) cell line, in order to evaluate the cytotoxicity
proﬁle and to further explore the possible presence of an off-target
effect for the newcompounds. TheMTTassaymeasures the effect of
molecules on cell proliferation and other events that eventually
lead to cell death [40].
Data are reported in Table 7 as minimum effective concentration
(MEC) related to a vehicle control (DMSO) and AC50. All tested
compounds showed a concentration-dependent decrease in for-
mazan production across the range studied (example plots in the
Supplementary data), indicating a decrease in cell viability associ-
ated with some growth inhibitory and toxic effects. Compared with
control (R)-bicalutamide (45a), the new compounds are in general
characterized by a higher cytotoxicity, with the lowest MEC and
AC50 values obtained for 23d, which is also one of the most active
compounds in the antiproliferative assay (antiproliferative data
Table 7).
These results might represent an important indication that the
newly prepared analogues, besides the canonical AR antagonist
activity, possess an extra effect, which positively contributes to
their antiproliferative action. Such effect seems to be particularly
evident for 23d, while other derivatives (e.g. 28m, 42b) do not
Table 5
Metabolic stability in human liver microsomes; * CLint: theoretical unrestricted maximum clearance of unbound drug by an eliminating organ, in absence of blood or plasma
protein binding limitations; ** SE: standard error; ***Compounds metabolically stable with no loss of parent detected for the duration of the assay.
Compound Ar (B ring) X R (A ring) Metabolic stability
CLint (mL/min/mg protein)* SE CLint** t1/2 (min)
45a (R-Bic.) 4-F-Ph SO2 4-CN, 3-CF3 6.48 2.52 214
44e (S-Eno) 4-CN-Ph O 4-CN, 3-CF3 Metabolically Stable***
22c 3-CF3-Ph S 4-CN, 3-CF3 232 5.89
5.97
22d 2-CF3-Ph S 4-CN, 3-CF3 379 12.8
3.66
23c 3-CF3-Ph S 4-NO2, 3-CF3 202 2.33
6.87
23d 2-CF3-Ph S 4-NO2, 3-CF3 409 46.8
3.39
27b 4-CF3-Ph O 4-CN, 3-CF3 Metabolically Stable***
28m 4-CN,2-CF3-Ph O 4-NO2, 3-CF3 2.59 2.45
534
33d 2-CF3-Ph SO2 4-NO2, 3-CF3 Metabolically Stable***
42b 4-CF3-Ph S 4-CN, 3-CF3 248 11.8
5.60
42c 3-CF3-Ph S 4-CN, 3-CF3 302 5.66
4.59
Table 6
Caco-2 cell permeability test; * (A/ B): apical-basolateral ﬂux; ** (B/ A): basolateral-apical ﬂux; this informationwas used for the apparent permeability (Papp) evaluation;
***Efﬂux Ratio: Mean Papp B/ A/Mean Papp A/ B; yCompounds tested under standard conditions using HBSS buffer at pH¼ 7.4. All other compounds were tested under the
same conditions but the cell media contained BSA (1% w/v). All compounds were tested an initial concentration of 10 mM.
Compound Ar (B ring) X R (A ring) Permeability data
Mean Papp (A/ B) (x 106 cm s1)* Mean Papp (B/ A) (x 106 cm s1)** Efﬂux ratio BA/AB***
45a (R-Bic.)y 4-F-Ph SO2 4-CN, 3-CF3 32.0 38.1 1.19
44e (S-Eno.)y 4-CN-Ph O 4-CN, 3-CF3 31.5 26.7 0.848
22c 3-CF3-Ph S 4-CN, 3-CF3 3.92 4.73 1.21
22d 2-CF3-Ph S 4-CN, 3-CF3 3.08 7.12 2.31
23c 3-CF3-Ph S 4-NO2, 3-CF3 5.00 4.27 0.853
23d 2-CF3-Ph S 4-NO2, 3-CF3 3.44 2.90 0.843
27b 4-CF3-Ph O 4-CN, 3-CF3 5.09 4.80 0.943
28m 4-CN,2-CF3-Ph O 4-NO2, 3-CF3 4.35 3.49 0.803
33dy 2-CF3-Ph SO2 4-NO2, 3-CF3 13.3 17.2 1.29
42b 4-CF3-Ph S 4-CN, 3-CF3 5.80 4.74 0.817
42c 3-CF3-Ph S 4-CN, 3-CF3 6.84 12.2 1.78
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show a signiﬁcant increase in cytotoxicity, maintaining instead a
remarkable improvement in the antiproliferative assay in com-
parison with bicalutamide. The mechanism and effect (necrosis,
apoptosis, reduction of cellular proliferation or effect on mito-
chondria) causing this cytotoxicity, which seems to be a conse-
quence of the new structural modiﬁcations, will be the main focus
of future studies.
3. Conclusions
The structures of bicalutamide and enzalutamide, two non-
steroidal androgen receptor antagonists in use to treat prostate
cancer, have been chemically modiﬁed leading to the synthesis of
new and more potent antiproliferative compounds. Different
chemical modiﬁcations have been planned in order to beneﬁt from
the properties of ﬂuorine in improving the activity and pharma-
cological proﬁle of drugs. The novel chemical entities were found to
be full androgen receptor (AR) antagonists, with no residual agonist
effect found also for structural analogues of enobosarm (ether de-
rivatives), a well-known AR partial agonist. Introduction of extra
perﬂuoro groups (CF3 and OCF3) confers metabolic stability to
phase I drug metabolizing enzymes, maintaining the same good
membrane permeability of the parent compounds. A very notable
improvement in the in vitro anti-proliferative effect on four
different PC cell lines (VCap, LNCaP, DU-145 and 22RV1) has been
achieved, improving the activity of the parent structures up to 50
folds, thus making some of the new molecules potential drug
candidates for the treatment of prostate cancer. This marked ac-
tivity improvement did not parallel an enhanced AR antagonistic
effect. Moreover, increased cytotoxicity found for some of the new
analogues in the MTT assay could be an indication that the com-
pounds developed in this work, while certainly binding to AR LBD
and exhibiting full antagonist behaviour, might possess another
biological effect, which positively contributes to their anti-
proliferative action in the prostatic cancer cell lines. The reliable AR
homology model prepared and all the docking information pro-
vided can offer useful insights for the development of pure AR
antagonists. The new model appears well validated by all observed
data.
The results achieved in this work will be the starting point for
further modiﬁcation of the parent compounds, in order to improve
both antiproliferative and anti-androgen properties. All successful
structural modiﬁcations will be further investigated, giving priority
to the replacement of the central methyl group of bicalutamide
with a CF3 (52).
Future biological studies will aim to understand the mechanism
of action and the biological consequences of potential off target
effects, along with the evaluation of our novel AR antagonists in a
W741L mutant AR. Finally, the most promising compound for each
structural family (23d, 27b, 33d) has been selected for in vivo pre-
clinical studies in mouse models.
4. Experimental
All chemistry, biology and molecular modelling experimental
procedures, along with compound characterisation, are fully
described in the Supplementary Data. All ﬁnal compounds were
puriﬁed by column chromatography or recrystallization, fully
characterised by NMR (1H, 13C, 19F) and LRMS. HRMS is reported for
representative ﬁnal compounds (one example for each synthetic
method). All ﬁnal compounds were found to be >95% pure by HPLC.
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